SCHEMBL7364941

SCHEMBL7364941

C[C@H](N)C(=O)NCCc1ccc(O)c(O)c1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.65
HSD17B10 Q99714 3/20 0.65
HIF1A Q16665 2/20 0.65
KDM4E B2RXH2 2/20 0.65
ALDH1A1 P00352 2/20 0.65
LMNA P02545 2/20 0.65
HPGD P15428 2/20 0.65
BLM P54132 2/20 0.65
PTGS1 P23219 1/20 0.65
GLI1 P08151 1/20 0.56
GLI2 P10070 1/20 0.56
HDAC8 Q9BY41 1/20 0.56
ERCC1 P07992 2/20 0.55
ERCC4 Q92889 2/20 0.55
TP53 P04637 1/20 0.54
CYP1A2 P05177 1/20 0.54
ALOX15 P16050 1/20 0.54
TSHR P16473 1/20 0.54
NFKB1 P19838 1/20 0.54
MAPK1 P28482 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30281537 1.00 MAPT (0.65) MAPTHSD17B10HIF1AKDM4EALDH1A1
SCHEMBL28976208 1.00 MAPT (0.65) MAPTHSD17B10HIF1AKDM4EALDH1A1
SCHEMBL28976184 0.88 MAPT (0.61) MAPTHSD17B10HIF1AKDM4EALDH1A1
SCHEMBL9965254 0.88 ERCC1 (0.71) MAPTHSD17B10HIF1AKDM4EALDH1A1
SCHEMBL4949922 0.86 MAPT (0.67) MAPTHSD17B10HIF1AKDM4EALDH1A1
SCHEMBL5053837 0.86 MAPT (0.67) MAPTHSD17B10HIF1AKDM4EALDH1A1
SCHEMBL28976207 0.86 MAPT (0.58) MAPTHSD17B10HIF1AKDM4EALDH1A1
SCHEMBL31475411 0.85 MAPT (0.65) MAPTHSD17B10HIF1AKDM4EALDH1A1
SCHEMBL1123655 0.85 MAPT (0.65) MAPTHSD17B10HIF1AKDM4EALDH1A1
SCHEMBL27269169 0.85 MAPT (0.65) MAPTHSD17B10HIF1AKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0106335-B1 PHARMACEUTICAL COMPOSITION AND A METHOD FOR ENHANCING THE ABSORPTION OF A PHARMACEUTICALLY ACTIVE COMPOUND Tanabe Seiyaku Co., Ltd. (JP) 1991-10-23 EP claimed
EP-0106335-A2 Pharmaceutical composition and a method for enhancing the absorption of a pharmaceutically active compound Tanabe Seiyaku Co., Ltd. (JP) 1984-04-25 EP claimed
CN-119950467-A Application of N-beta-alanyl dopamine or salt thereof in preparation of product for preventing and treating hepatic fibrosis 首都医科大学 2025-05-09 CN disclosed
US-11904014-B2 Immunostimulatory compositions Assistance Publique—Hopitaux de Paris (FR) 2024-02-20 US disclosed
EP-3380120-A1 IMMUNOSTIMULATORY COMPOSITIONS Assistance Publique - Hôpitaux de Paris (FR) 2018-10-03 EP disclosed
WO-2017089529-A1 IMMUNOSTIMULATORY COMPOSITIONS ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (FR) 2017-06-01 WO disclosed
EP-0607394-A1 DIPHOSPHATES OF CATECHOLAMINES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM ZAMBON GROUP S.p.A. (IT) 1994-07-27 EP disclosed
WO-1994003461-A1 DIPHOSPHATES OF CATECHOLAMINES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM ZAMBON GROUP S.P.A. (IT) 1994-02-17 WO disclosed
EP-0106335-B1 PHARMACEUTICAL COMPOSITION AND A METHOD FOR ENHANCING THE ABSORPTION OF A PHARMACEUTICALLY ACTIVE COMPOUND Tanabe Seiyaku Co., Ltd. (JP) 1991-10-23 EP disclosed
EP-0106335-A2 Pharmaceutical composition and a method for enhancing the absorption of a pharmaceutically active compound Tanabe Seiyaku Co., Ltd. (JP) 1984-04-25 EP disclosed
EP-0007441-B1 N - (N-ACETYL-L-METHIONYL) - 3,4 -DIETHOXY-CARBONYLOXY-PHENETHYLAMINE, PROCESS FOR PREPARING SAME AND A PHARMACEUTICAL COMPOSITION CONTAINING SAID COMPOUND. Tanabe Seiyaku Co., Ltd. (JP) 1981-11-25 EP disclosed
US-4228183-A HYPOTENSIVE AGENTS TANABE SEIYAKU CO., LTD. (JP) 1980-10-14 US disclosed
EP-0007441-A1 N - (N-Acetyl-L-methionyl) - 3,4 -diethoxy-carbonyloxy-phenethylamine, process for preparing same and a pharmaceutical composition containing said compound. Tanabe Seiyaku Co., Ltd. (JP) 1980-02-06 EP disclosed
US-4033997-A Preparation of dopamine derivatives ABBOTT LABORATORIES (US) 1977-07-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11904014-B2 Immunostimulatory compositions CD47, CD74, LY96 MAPT 1875/4885HSD17B10 3511/4885HIF1A 516/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.